Explore published findings of medical trials and real-world evidence.
This page includes links to Novo Nordisk-sponsored trials and observational research published in peer reviewed journals. The list of publications below is sorted by product and limited to products that have been approved for use. Please note that publications may contain information about doses, delivery devices, uses, formulations and/or populations that differs from FDA-required labeling. Novo Nordisk does not suggest or recommend the use of its products in any manner other than as described in their FDA-required labeling, which is findable under each product below.
Products are listed in order of the most recent FDA approval, with the most recent shown first.
(concizumab-mtci) injection 60 mg, 150 mg, or 300 mg | Full Prescribing Information
Published Date: August 31, 2023
Published Date: January 7, 2026
No publications available
Find more information
Find product information
Explore our portfolio of products for treating rare bleeding disorders, including prescribing information, safety data sheets and storage and stability information.
Continuing education
Learn about accredited rare bleeding disorders education opportunities supported by Novo Nordisk and provided by third-party organizations.